SCHEMBL17467271

SCHEMBL17467271

c1ccc(-c2ccc(-c3nc(-c4ccccc4)nc(-c4cc(-c5ccccc5)cc(-c5cccc6c5Cc5ccccc5-6)c4)n3)cc2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 2/20 0.41
ADORA1 P30542 2/20 0.41
PNMT P11086 1/20 0.39
KDR P35968 1/20 0.38
MEN1 O00255 3/20 0.37
KMT2A Q03164 3/20 0.37
ALDH1A1 P00352 2/20 0.37
MAPT P10636 2/20 0.37
HPGD P15428 2/20 0.37
KDM4E B2RXH2 1/20 0.36
LMNA P02545 1/20 0.36
GLA P06280 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.35
SRD5A2 P31213 1/20 0.35
ACHE P22303 2/20 0.35
BCHE P06276 1/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
CHEK1 O14757 1/20 0.35
NTSR1 P30989 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17467267 1.00 ADORA2A (0.41) ADORA2AADORA1PNMTKDRMEN1
SCHEMBL17467277 1.00 ADORA2A (0.41) ADORA2AADORA1PNMTKDRMEN1
SCHEMBL17467263 1.00 ADORA2A (0.41) ADORA2AADORA1PNMTKDRMEN1
SCHEMBL17467261 0.99 ADORA2A (0.42) ADORA2AADORA1PNMTKDRMEN1
SCHEMBL17467283 0.99 ADORA2A (0.42) ADORA2AADORA1PNMTKDRMEN1
SCHEMBL17467275 0.97 ADORA2A (0.40) ADORA2AADORA1PNMTKDRMEN1
SCHEMBL17467262 0.97 ADORA2A (0.41) ADORA2AADORA1PNMTKDRMEN1
SCHEMBL17467299 0.97 ADORA2A (0.41) ADORA2AADORA1PNMTKDRMEN1
SCHEMBL17467269 0.96 ADORA2A (0.40) ADORA2AADORA1PNMTKDRMEN1
SCHEMBL17467298 0.94 ADORA2A (0.41) ADORA2AADORA1PNMTKDRMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11818949-B2 Organic electroluminescent materials and devices UNIVERSAL DISPLAY CORPORATION (US) 2023-11-14 US disclosed
US-11641774-B2 Organic electroluminescent materials and devices UNIVERSAL DISPLAY CORPORATION (US) 2023-05-02 US disclosed
US-20230130110-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION (US) 2023-04-27 US disclosed
US-20230126221-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION (US) 2023-04-27 US disclosed
US-20170054087-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION (US) 2017-02-23 US disclosed
US-20170025618-A1 Organic Electroluminescent Materials and Devices UNIVERSAL DISPLAY CORPORATION 2017-01-26 US disclosed
US-20160093808-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION (US) 2016-03-31 US disclosed
US-20160028021-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION (US) 2016-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160028021-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES OCIAD2, OCIAD1, OR10J3 ADORA2A 4607/4885ADORA1 4447/4885PNMT 2316/4885
US-20230130110-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES SOD1, PIEZO1, L1CAM ADORA2A 4012/4885ADORA1 4079/4885PNMT 482/4885
US-11818949-B2 Organic electroluminescent materials and devices EML4, TBCB, TERF2IP ADORA2A 3792/4885ADORA1 4162/4885PNMT 18/4885
US-20170025618-A1 Organic Electroluminescent Materials and Devices TBCB, EML4, INMT ADORA2A 3210/4885ADORA1 4015/4885PNMT 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.